ALNY Stock Recent News
ALNY LATEST HEADLINES
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors.
Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the study could drive the share price to the high-$200 range, while a failure could lead to a drop towards $100. The key question is whether HELIOS-B shows a meaningful efficacy benefit for Amvuttra versus a high bar established by rival compounds.
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants David Lebowitz – Citi Paul Matteis – Stifel Maury Raycroft – Jefferies Gary Nachman – Raymond James Tazeen Ahmad – BofA Securities Ritu Baral – TD Cowen Jessica Fye – JPMorgan Kostas Biliouris – BMO Capital Markets Ellie Merle – UBS Gena Wang – Barclays Mike Ulz – Morgan Stanley Whitney Ijem – CG Operator Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Quarter One 2024 Conference Call.
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.40 per share a year ago.
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2024 results as well as expectations for the future via conference call on Thursday, May 2, 2024 at 8:30 am ET. To access the call, please r.